inclisiran

The Medicines Company (NASDAQ: MDCO) shares have been on a roll. After picking up some momentum Aug 21, the stock rallied strongly Aug. 26 after the company reported top-line results from the ORION-11 study. The stock continued to rally ahead of the presentation of the detailed results of the...

The Medicines Company (NASDAQ: MDCO) gave a sneak-peek of results from a late-stage trial of its proprotein convertase subtilisin/kexin type 9,or PCSK9 inhibitor inclisiran Monday morning ahead of presentation as a late-breaking science session Sept. 2 at the European Society of Cardiology...

The Medicines Company (NASDAQ: MDCO) stock has staged a nice recovery in the first half of 2019 after a steep 60% pullback in the second half of 2018 that dragged it to a 52-week low of $16.69 on Dec. 21. From the low, the stock rallied to an intraday peak of $38.96 on July 11, 2019, a 133%...

Small-cap biotech The Medicines Company (NASDAQ: MDCO) announced long-term results over the weekend from a midstage study of its lead product candidate Inclisiran, sending its shares higher. What Happened Medicines Company announced interim results Saturday from the ongoing Phase 2 ORION-3 study...

Following the impressive phase II ORION-1 results for the RNAi drug, inclisiran (a PCSK9 inhibitor for hypercholesterolemia), inclisiran's “expeditious” movement into phase III trials, the injunction granted against Praluent (another PCSK9 inhibitor) Thursday and with PCSK9...

HC Wainwright has started coverage of The Medicines Company (NASDAQ: MDCO) with a Buy rating and $57 price target on the back of Phase 3-ready inclisiran (PCSK9si). Key Catalyst: Inclisiran Inclisiran is an RNAi therapeutic that inhibits synthesis of PCSK9 directly in the liver for potent and...